DENN domain containing 6BGenealiases: AFI1B · FAM116B
Q-omics provides the consensus-scored DENND6B profile across patient tissues and cancer cell-line models. DENND6B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, DENND6B is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, DENND6B RNA expression shows 17,386 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight COAD, KIRC, and ACC as cancer lineages where DENND6B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DENND6B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DENND6B survival associations across molecular data types. DENND6B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DENND6B RNA expression–survival associations across cancer types. High DENND6B expression shows unfavorable associations in COAD, ACC and LIHC, but favorable associations in KIRP, UCEC and BLCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify COAD as the clearest survival context for DENND6B RNA expression.
This table summarizes DENND6B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DENND6B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DENND6B shows lower tumor expression in KICH, LUSC and LUAD and higher tumor expression in KIRC, LIHC and THCA. The KIRC box plot shows higher DENND6B RNA expression in tumor versus normal tissue (log2 FC = +0.460, t-test p < 0.001).
This table shows molecular features associated with DENND6B in patient tissues and cancer cell lines. In patient samples, DENND6B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DENND6B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
